Table 1 Demographics and clinical characteristics of CML cohort
Total CML-CP Patients (n=303) | |
|---|---|
Gender (n, %) | |
Male | 140 (46.2%) |
Female | 163 (53.8%) |
Age (mean years, SD) | 51.5 (±13.6) years |
Time since CML diagnosis (mean years, SD) | 4.8 (±4.5) years |
Time since CML diagnosis (n, %) | |
<2 years | 76 (25.1%) |
2 to <5 years | 90 (29.7%) |
≥ 5 years | 136 (44.9%) |
Unknown | 1 (0.3%) |
Country (n, %) | |
USA | 152 (50.2%) |
Italy | 37 (12.2%) |
Germany | 33 (10.9%) |
Spain | 32 (10.6%) |
United Kingdom | 25 (8.3%) |
France | 24 (7.9%) |
Time on Current CML Treatment (median years, IQR) | 2.75 (4.8) |
Current CML Treatment (n, %) | |
Imatinib | 208 (68.6%) |
Nilotinib | 49 (16.2%) |
Dasatinib | 38 (12.5%) |
Other | 4 (1.3%) |
Decline to answer | 4 (1.3%) |
No. of Comorbidities (mean, SD) | 1.4 (±2.4) |
Comorbidities (n, %) | |
Hypertension | 49 (16.2%) |
Insomnia/sleep difficulties | 32 (10.6%) |
Depression | 25 (8.3%) |
Arthritis | 24 (7.9%) |
Anxiety | 24 (7.9%) |
Anemia | 21 (6.9%) |